Loading clinical trials...
Loading clinical trials...
This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD-0360324 in patients with cutaneous lupus erythematosus. Changes in disease activity wi...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT06875960 · Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
NCT05411016 · Healthy Volunteers, Systemic Lupus Erythematosus (SLE), and more
NCT05629208 · Cutaneous Lupus Erythematosus (CLE)
NCT04781816 · Cutaneous Lupus Erythematosus
NCT03817424 · Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and more
Pfizer Investigational Site
Anniston, Alabama
Pfizer Investigational Site
Oxford, Alabama
Pfizer Investigational Site
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions